Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00303992|
Recruitment Status : Completed
First Posted : March 17, 2006
Last Update Posted : January 17, 2018
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving trastuzumab together with irinotecan may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving trastuzumab together with irinotecan works in treating patients with HER2/neu positive metastatic breast cancer.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Biological: trastuzumab Drug: irinotecan hydrochloride||Phase 2|
- Determine the overall objective response-rate (partial and complete) and stable disease rate in patients with HER2/neu positive metastatic breast cancer treated with the combination of irinotecan hydrochloride and trastuzumab (Herceptin®) after prior first- or second-line therapy with trastuzumab combined with other chemotherapeutic agents.
- Determine the toxicities of this combination regimen.
- Determine the duration of response and time to disease progression in patients treated with this combination.
- Document development of brain metastases or progression of known metastases in patients treated with this regimen.
OUTLINE: Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, 15, and 22 and irinotecan hydrochloride IV over 30-60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial|
|Study Start Date :||May 2004|
|Actual Primary Completion Date :||November 16, 2006|
|Actual Study Completion Date :||January 2013|
|Experimental: Trastuzumab and Irinotecan||
Drug: irinotecan hydrochloride
- Overall objective response rate (partial and complete responses) [ Time Frame: up to 20 months post treatment ]
- Stable disease rate [ Time Frame: up to 20 months post treatment ]
- Toxicity [ Time Frame: up to 20 months post treatment ]
- Duration of response [ Time Frame: up to 20 months post treatment ]
- Time to disease progression [ Time Frame: up to 20 months post treatment ]
- Development of brain metastases or progression of known metastases on this treatment [ Time Frame: up to 20 months post treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00303992
|United States, California|
|UCSF Helen Diller Family Comprehensive Cancer Center|
|San Francisco, California, United States, 94115-1710|
|Principal Investigator:||Hope S. Rugo, MD||University of California, San Francisco|
|Principal Investigator:||Judy M. Cheng, MD, PhD||University of California, San Francisco|